© 2026 Sinochem Nanjing Corporation,
All Right Reserved
People learned about Trelagliptin Succinate through long years of diabetes research. Diabetes didn’t start as a global crisis overnight, but as the numbers climbed, scientists and pharmaceutical companies pushed for better, easier solutions. DPP-4 inhibitors came onto the scene after researchers found blocking DPP-4 could help control blood glucose without the roller coaster of highs and lows that earlier drugs brought. Trelagliptin grew out of this line of discovery. Japanese researchers and Takeda Pharma worked closely, aiming for a once-weekly pill rather than the daily dosing other DPP-4 inhibitors demanded. They saw busy patients skip doses, lose faith, and develop complications. In 2015, Japanese regulators approved Trelagliptin Succinate for type 2 diabetes, giving patients that extra breathing room between doses and showing the world that innovation isn’t just about chemistry—it’s about real life, real schedules, and the need for something that fits into the day without hassle.
You’ll usually see Trelagliptin Succinate as a white to light-yellow, odorless, crystalline powder. Most providers ship it as tablets for oral use. What stands out is the once-a-week dosing, which is a game-changer for people balancing careers, families, and their own health. With fewer pills, patients miss fewer doses, and the chance of long-term complications goes down—a win for the person, not just the product sheet. Medical practices in Asia, especially Japan, have adopted it for patients who have trouble sticking to intense pill schedules, and reports from doctors keep pointing out the ease of use and smoother blood sugar trends.
Looking at Trelagliptin Succinate from a chemist’s perspective, it has a molecular formula of C22H23F2N5O4·C4H6O4 and boasts a molecular weight hovering around 593.6 g/mol. In powdered form, this medicine resists moisture and keeps well under standard lab conditions. Its water solubility fits with tablet formulation needs, so manufacturers don’t wrestle with unnecessary hurdles in blending or pressing the drug. Finger-point tests in labs show its melting point sits above room temperature—stable enough for storage and shipping around the globe, especially during those humid months that trip up less robust ingredients.
Each package makes dosing clear: 100 mg strength tablets, meant for oral intake once a week. Labels, especially in Japan and across Asia, stick to tight regulations about listing excipients, storage conditions (cool, dry, without direct light), and warnings for special groups like children, pregnant women, and anyone with kidney troubles. You’ll notice clear batch numbers, expiration dates, and manufacturer details—details that keep the product traceable in the case of recalls or rare side effects. Boxes and bottles stay tamper-proof, which matters when trust and patient safety hang in the balance.
Manufacturers start by synthesizing the core structure through several organic reactions, assembling the fluorinated aromatic groups and the aminopiperidine backbone. It takes several steps: condensation, alkylation, and succinate salt formation. Each step adds value in terms of bioavailability and chemical stability. Engineers run strict purification steps, checking for impurities at every stage. At the end, they combine the free base with succinic acid to form the stable salt, which mixes cleanly with tablet fillers. Tight controls at every junction keep the yields dependable and reduce the chance of dangerous byproducts sneaking through.
Scientists have experimented with Trelagliptin’s structure, tweaking different substituents to fine-tune its DPP-4 inhibition. Substituting various aromatic groups or adjusting the succinate moiety led to modifications in potency, bioavailability, and even side effect patterns. These deep dives revealed that the difluorophenyl group, paired with aminopiperidine, best balances metabolic stability and activity. Some labs have explored salt forms other than succinate, but none have matched the original’s profile for stability, so the industry has stuck to the original recipe.
Doctors and pharmacists also know Trelagliptin as SYR-472. In Japan, you’ll find it under the brand name Zafatek. Pharmacopoeias and research journals list every synonym to avoid confusion—especially in an age where counterfeits and online pharmacies make the rounds. Healthcare professionals and researchers stay vigilant, checking not only the label, but also chemical abstracts numbers and supplier codes, making sure patients end up with the real thing every time.
Every batch faces rigorous safety checks before leaving the plant. Manufacturing follows PIC/S GMP standards and strict Japanese regulatory guidelines, which require validation of every critical process and cleaning step. Workers rely on PPE when handling the raw powder, since inhalation risks linger, especially during weighing and mixing phases. Facilities use closed systems and negative pressure to keep workers safe. Pharmacovigilance teams track patient data, on the lookout for rare allergic reactions or unexpected side effects. The reporting web—from manufacturers to clinics and regulatory bodies—catches adverse events quickly, which builds trust in the safety of long-term use.
Doctors prescribe Trelagliptin Succinate strictly for Type 2 diabetes. It doesn’t replace insulin or suit patients with Type 1. Its real strength shows up in community clinics serving older patients, shift workers, or anyone who routinely forgets daily pills. Combination therapy shows promise, especially for those with hypertension or high cholesterol, though labeling urges regular liver and kidney function tests. Most guidelines recommend it as an add-on when diet, exercise, and metformin alone can’t cut it. In a crowded drug market, its once-weekly schedule stands out as a practical advance, not a theoretical one.
Research teams keep studying Trelagliptin Succinate’s long-term effects, both in Japan and worldwide. Current trials explore whether less frequent dosing can help with “pill fatigue”—a stubborn problem among chronic disease patients. Some studies measure outcomes like A1c reduction and side effects in different ethnic groups, and others check for unexpected drug interactions in complex regimens. The research community also wants to know if the same mechanism could work for conditions beyond diabetes, like obesity or metabolic syndrome. Publications in international journals make it clear: the once-weekly idea has inspired pharma companies to reconsider dosing for other chronic medications, aiming for patient-centric care.
Any new diabetes medicine draws tough scrutiny for side effects, whether in mice, dogs, or patients. Toxicologists have checked for acute poisoning, organ toxicity, and reproductive risks. Animal studies point to a reliable safety margin—most adverse effects show up only at doses way higher than the recommended clinical ones. In humans, the most common problems mirror the class—mild upper respiratory infections or gastrointestinal symptoms. Japanese post-marketing surveillance tracks everything from rare liver toxicity reports to extremely infrequent anaphylactic reactions, offering a safety net that’s both wide and responsive.
Looking ahead, the Trelagliptin story isn’t just about treating diabetes—it’s about changing how people take medicine for chronic problems. Pharmacies in Japan see prescription refill rates climb, and clinics notice fewer patients getting hospitalized for poor blood sugar control. Some research labs are developing combination pills that would add statins or blood pressure medicines into one weekly dose, hoping to shave down “pill burden” for the millions who juggle several chronic diseases. Others explore next-generation DPP-4 inhibitors, learning from Trelagliptin’s weekly formula and aiming for monthly or even quarterly dosing. With more global approvals and open collaboration among researchers, Trelagliptin could set the stage for future treatments that put patient lives, not just chemical formulas, at the center of medicine.
Trelagliptin succinate sounds technical, but its purpose touches lives everywhere. It belongs to a group of drugs called DPP-4 inhibitors, and health professionals often bring it up in the conversation about treating type 2 diabetes. For many people living with fluctuating blood sugar, this medicine represents hope—not flashy or world-changing, but steady and reliable, the kind of help that lets someone focus on the rest of their life.
Trelagliptin works by boosting the body’s own hormones that manage blood sugar. After a meal, these hormones increase insulin from the pancreas and curb the production of more sugar in the liver. Trelagliptin extends the life of these hormones. The result is less chaos with glucose levels. People don’t experience as many dangerous spikes after eating, and there’s a lower risk of mishaps with low blood sugar compared to some older diabetes drugs.
Doctors have long looked for treatments that are easy to take and keep people safe. A key feature of trelagliptin is its once-weekly dosing. That stands out in a medical landscape full of daily routines. For people juggling busy schedules, family stress, or just the fatigue that comes from living with a chronic disease, the weekly tablet means one less thing to remember every single day. Missing doses less often raises the chance of getting the full benefit.
Healthcare isn’t just about lab numbers or statistics; it connects directly to everyday life. Diabetes hasn’t just shown up in my family history books. I have watched relatives and friends manage their sugars, count out tablets by the week, and talk honestly about how frustrating some regimens can feel. Whatever helps simplify their day and keep their dignity matters. Trelagliptin reflects a newer mindset—medicine should fit into life, not take it over.
Poorly managed type 2 diabetes harms blood vessels, kidneys, eyes, and nerves. That makes medications that stabilize glucose levels important beyond comfort; they help reduce life-changing complications. Clinical studies from Japan and other parts of Asia report lower fasting blood sugars and significant improvements in HbA1c (a marker of long-term control) when people use trelagliptin.
Access remains a challenge. Trelagliptin isn’t available everywhere, as regulatory approvals and insurance policies differ by country. This limits many people’s options, pinning choices to what doctors and health systems can offer. If decision-makers see the way drugs like trelagliptin support real lives—not just check boxes in clinical trials—they could push for broader access and better affordability.
Education stands as another front. Many still don’t know about newer medicines or are wary to switch treatment without full understanding. Doctors, nurses, and pharmacists could lead more conversations about medication choices. Talking through side effects, long-term expectations, and concerns about cost gives people the knowledge to make decisions that fit their own lives.
Trelagliptin succinate gives one more tool for fighting back against the daily challenges of diabetes. By pushing for access and keeping real people’s stories at the center, we shape a healthcare landscape where more can thrive—not just survive.
Let’s cut through the medical jargon. Trelagliptin succinate steps into the world of diabetes care as a member of the DPP-4 inhibitor family. For people dealing with type 2 diabetes, finding a way to help the body manage blood sugar feels like a daily balancing act. That balancing act gets a little less painful when there’s a medicine that works and doesn’t demand a pocket full of pills.
Trelagliptin succinate focuses on enzymes in the intestine called Dipeptidyl Peptidase-4, or DPP-4 for short. These enzymes break down hormones called incretins, which help the body put out more insulin when blood sugar climbs up after a meal. With DPP-4 turned down, incretins stay around longer. More incretins means the pancreas knows to send out more insulin, lowering sugar in the bloodstream without making sugar crash dangerously low.
Spending time with friends who battle blood sugar swings, I’ve seen countless doses forgotten or delayed. Here’s where Trelagliptin succinate stands out: the once-a-week tablet takes a weight off the shoulders. Doctors and patients both tell me how fewer pills mean better routines and greater willingness to stick to treatment. Research published over the last decade backs this up, with adherence rates showing improvement just by switching from daily to weekly dosing options in diabetes care.
Living with type 2 diabetes means walking a tightrope between too high and too low. Solutions that dodge big swings in blood sugar matter. Trelagliptin succinate’s approach doesn’t push insulin beyond what the body already would try to do with a meal. It works with the body’s signals instead of trying to overpower them. This means a lower risk of hypoglycemia—the dreaded rapid sugar crash that keeps so many people up at night.
Weight gain often follows on the heels of many diabetes treatments. From chatting with people in diabetes support groups, weight keeps coming up as a concern. Since DPP-4 inhibitors don’t cause weight spikes, many patients see that as a win. The Japanese health system, which first approved trelagliptin succinate, has reported good results in both sugar control and patient safety. Longer-term findings keep pointing to benefits beyond just numbers on a chart.
No diabetes drug works alone. Trelagliptin succinate won’t replace healthy eating, exercise, and regular checkups. The drug’s track record for once-a-week convenience, stable blood sugar, and a lower side effect burden make it a strong addition to the mix. The World Health Organization and diabetes associations worldwide keep reminding us that sticking to treatment builds better lives over time.
Getting Trelagliptin succinate into wider use takes a team effort—doctors educating, patients asking questions, and healthcare systems making sure it’s available. In my work connecting with patients and providers, those using the drug mention feeling less overwhelmed, which translates to stronger commitment over months and years. More studies and real-world feedback should guide updates in treatment plans. If we listen to what works for patients, the whole system benefits.
Trelagliptin succinate stands as a real-world example of thoughtful medicine—balancing science and daily life for people fighting to manage diabetes each day.
Trelagliptin Succinate stands out as a once-weekly pill used by people living with type 2 diabetes. Its main job is lowering blood sugar, helping the pancreas boost insulin, and stopping the liver from sending out too much glucose. It works by blocking the DPP-4 enzyme, letting more of that helpful hormone called incretin stick around longer in the blood.
Nobody reaches for medication hoping to feel lousy, yet even a modern diabetes drug like this one brings along some unwanted feelings. One pattern that keeps coming up in clinics and studies: folks often complain about stomach troubles. The most typical stories include:
Doctors see these shifts in the gut most often. It rarely surprises me, since most DPP-4 drugs seem to tug on the digestive system. A light meal and plenty of water sometimes take the edge off.
Modern diabetes treatments like this one do a solid job holding blood sugars steady, but some folks worry about what might show up after years of use. So far, longer studies haven’t found any new pattern of nerve or organ problems caused by this drug. Liver and kidney panels tend to look the same as with other DPP-4 blockers. Still, I follow up with regular blood tests, just to keep an eye open for surprises.
The best way to dodge side effects often starts with honest talk at the first appointment. Letting your doctor know about stomach or allergy trouble early can mean a dose change or a shift in timing that makes the drug less bothersome. Blood tests every few months help track liver and kidney health, and simple lifestyle moves—think exercise, good hydration, smaller meals—soften the blow of most digestive complaints. Pharmacists remain an underused tool as well; they catch drug interactions and suggest the right time of day to pop a pill.
Most people taking Trelagliptin Succinate get solid sugar control without too much drama. Monitoring, honest conversation, and a willingness to tweak the plan go a long way toward staying both safe and comfortable on this treatment.
Trelagliptin Succinate falls into a group called DPP-4 inhibitors, which help people with type 2 diabetes manage blood sugar levels. Unlike the daily pills so many folks swallow, Trelagliptin comes as a once-weekly tablet. The relief from not having to remember a daily pill can feel like a small but real win in the middle of managing diabetes.
Doctors usually recommend taking Trelagliptin Succinate just once a week, on the same day each week. That day turns into an easy marker—some tie their dose to their favorite TV show or the day laundry gets done. Pairing it with a certain routine makes the dose hard to forget. Missing doses with once-weekly medications often leads to sugar swings that are tough to untangle later, so building a routine makes sense.
Trelagliptin Succinate can be swallowed any time of the day, with or without food. If digestion troubles come up, taking it after a meal can help settle the stomach. Swallow the tablet whole, chased down with a glass of water—do not split or crush. The design matters because breaking tablets can mess up how the medicine works. Many folks want to tweak tablets for convenience, but with Trelagliptin, the pill’s coating isn’t just for looks.
Self-medicating or sharing doses with family members doesn’t mix well with Trelagliptin Succinate. Doctors watch closely for side effects or allergic reactions, adjusting medication based on how bodies and blood sugars respond. If kidneys don’t filter as well as they used to, doctors might lower the dose or suggest something altogether different. Kidney health guides many diabetes medication choices for clear reasons—most DPP-4 drugs break down in the kidneys, and if things slow down, medication can linger and cause trouble.
Look out for allergy signs: itchy skin, swelling, or breathing problems. If blood sugar drops too low, shakes, dizziness, or confusion can show up. Combining Trelagliptin Succinate with other diabetes pills or insulin increases this risk. I’ve seen friends breeze through weeks on this medication, but mixing it with sulfonylureas or heavy exercise without snacks led to surprises—sometimes scary ones. Keep fast-acting sugar on hand and watch for patterns that suggest a routine tweak or doctor’s visit is necessary.
Alcohol can make blood sugar hard to control. It's smart to talk to your doctor if you drink often, since adding alcohol muddies the effects of most diabetes medications, not just Trelagliptin.
Storing this medication doesn't require the fridge. Keep it dry, in a drawer away from sunlight, and out of reach of children. Simple habits like these help avoid unnecessary accidents.
Life with diabetes never feels one-size-fits-all. Even with once-weekly dosing, Trelagliptin Succinate works best when you check sugars regularly and bring honest questions to your healthcare appointments. Pharmacists often know shortcuts for fitting a new pill into daily life or side-step costs with generic suggestions or coupons. Using their expertise can help the medicine work its best for you.
Learning about a drug like Trelagliptin Succinate matters when diabetes patients live with kidney or liver problems. Most people, including friends or family I know, judge a medicine by how well it handles the main problem, not realizing these drugs work through the gut, liver, and kidneys. From several clinical studies, Trelagliptin Succinate, which falls into the DPP-4 inhibitor family, often shows promise for blood sugar control. But what about patients who already deal with a heavy kidney burden, or have faced hepatitis or cirrhosis?
Research out of Japan, where Trelagliptin got its approval, tells us something important: study groups looked at adults with mild to moderate kidney impairment. Blood tests did not show alarming changes in kidney markers, even after a year of use. Doctors monitored creatinine and eGFR numbers closely and saw few jumps compared to people not taking the drug. One large multicenter study published in Diabetes, Obesity & Metabolism tracked real-world patients and found that most kept stable kidney function. Several colleagues who see tough kidney cases say they still approach new drugs cautiously, because every organ that helps clear a medicine matters in these patients.
Looking at the liver, there’s less data. Earlier studies included some adults with mild liver trouble, such as steatosis or mild chronic hepatitis. No outbreaks of liver failure, jaundice, or significant enzyme jumps turned up in these trials. I’ve seen patients with fatty liver disease start a DPP-4 inhibitor like Trelagliptin and their bloodwork, including ALT and AST, usually stays steady. But severe liver impairment? Data falls short. Only a handful of case studies look at those with cirrhosis or liver transplants. Most physicians recommend skipping this drug for anyone with advanced hepatic failure until researchers fill this gap.
Trust grows with clear numbers and open discussion—not with industry handouts or promises. In truth, many diabetes drugs need lower doses or closer checks in people with kidney or liver problems. Trelagliptin’s once-weekly dose stands out, as daily pill burden stresses some older folks with poor kidney or liver reserve. Still, safety means more than just “no big side effects” during studies. Some long-term risks surface late. Doctors often start at a low dose, check labs every few months, and ask about new symptoms—itching, nausea, swelling—right away.
If someone with kidney problems cannot use metformin, sulfonylureas, or SGLT2 inhibitors safely, DPP-4 inhibitors like Trelagliptin may offer a path forward. My experience shows that open talks between patient and doctor matter most. People need to know how to recognize changes in their health, report odd symptoms quickly, and stay informed about their treatment. For anyone worried about interactions, always list every drug or supplement you take. This helps avoid hidden risks, especially with liver concerns.
Regulators and doctors still call for more data, especially for patients living with severe kidney or liver disease. Every patient brings their own risks, genetics, and other medicines to the table. Ongoing research will help fill in the blanks. Nobody should feel pushed into new medication without clear discussion about the risks, benefits, and other choices. In the end, real-world safety means trusting what experience, evidence, and careful teamwork can bring.
| Names | |
| Preferred IUPAC name | (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,6-trifluorophenyl)butan-2-amine succinate |
| Other names |
Zafatek SYR-472 |
| Pronunciation | /ˌtrɛləˈɡlɪptɪn səksɪˈneɪt/ |
| Identifiers | |
| CAS Number | 1029877-94-8 |
| Beilstein Reference | 12432937 |
| ChEBI | CHEBI:85250 |
| ChEMBL | CHEMBL3184632 |
| ChemSpider | 120973 |
| DrugBank | DB11604 |
| ECHA InfoCard | 100004007383 |
| EC Number | 3.4.14.6 |
| Gmelin Reference | 1613410 |
| KEGG | D10340 |
| MeSH | Dipeptidyl-Peptidase IV Inhibitors |
| PubChem CID | 71237280 |
| RTECS number | FZ4I2W161M |
| UNII | 39F11GIU10 |
| UN number | UN3465 |
| CompTox Dashboard (EPA) | FchoiceSDK0000674 |
| Properties | |
| Chemical formula | C18H21FN4O2·C4H6O4 |
| Molar mass | 475.53 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | Density: 1.5 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 0.5 |
| Acidity (pKa) | pKa = 8.7 |
| Basicity (pKb) | 8.86 |
| Magnetic susceptibility (χ) | -53.72×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.61 |
| Dipole moment | 3.7 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 303.7 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | A10BH08 |
| Hazards | |
| Main hazards | May cause eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | `ATC code: A10BH10` |
| Signal word | Warning |
| Hazard statements | Hazard statements: Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Store at room temperature, away from moisture and heat. Use only as directed by your physician. |
| Flash point | Flash point: 492.2°C |
| Lethal dose or concentration | LD₅₀ (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Trelagliptin Succinate: **greater than 2000 mg/kg (rat, oral)** |
| NIOSH | RS6QK3352V |
| PEL (Permissible) | Not established |
| REL (Recommended) | 100 mg once weekly |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Alogliptin Saxagliptin Sitagliptin Vildagliptin Linagliptin Teneligliptin Gemigliptin |
